Sun Pharmaceutical Industries Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Sun Pharmaceutical Industries hat ein Gesamteigenkapital von ₹671.1B und eine Gesamtverschuldung von ₹28.4B, wodurch sich der Verschuldungsgrad auf 4.2% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹854.6B bzw. ₹183.6B. Sun Pharmaceutical Industries Das EBIT des Unternehmens beträgt ₹104.3B, so dass der Zinsdeckungsgrad 43.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹191.1B.

Wichtige Informationen

4.2%

Verhältnis von Schulden zu Eigenkapital

₹28.44b

Verschuldung

Zinsdeckungsgrad	43.7x
Bargeld	₹191.05b
Eigenkapital	₹671.06b
Gesamtverbindlichkeiten	₹183.57b
Gesamtvermögen	₹854.63b

Jüngste Berichte zur Finanzlage

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Jun 15

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Mar 14

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Dec 09

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Sep 04

Recent updates

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Jun 30

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 25

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

May 22

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 03

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Jan 05

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Dec 18

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Oct 04

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Jul 03

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Jun 15

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Mar 14

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

Feb 03

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Dec 09

Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

Oct 13

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Sep 04

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Aug 05

Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Jul 12

Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Jun 02

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Apr 28

Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?

Apr 09

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00

Feb 02

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?

Feb 02

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Jan 19

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SUNPHARMADie kurzfristigen Aktiva des Unternehmens (₹434.7B) übersteigen seine kurzfristigen Passiva (₹169.8B).

Langfristige Verbindlichkeiten: SUNPHARMADie kurzfristigen Vermögenswerte des Unternehmens (₹434.7B) übersteigen seine langfristigen Verbindlichkeiten (₹13.7B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SUNPHARMA über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: SUNPHARMA Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 23.2% auf 4.2% zurückgegangen.

Schuldendeckung: SUNPHARMADie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (426.6%).

Zinsdeckung: SUNPHARMADie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (43.7x Coverage) gut gedeckt.

Sun Pharmaceutical Industries Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Recent updates

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately

Sun Pharmaceutical Industries Limited Announces Results from A Phase 1, Multiple Ascending-Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gl0034 (Utreglutide) in Obese Adults

Sun Pharmaceutical Industries Limited, Annual General Meeting, Aug 05, 2024

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million.

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

Sun Pharmaceutical Industries Limited to Report Q4, 2024 Results on May 22, 2024

Sun Pharmaceutical Industries Limited Announces Executive Changes

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million.

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to ₹8.50

Price target increased by 9.3% to ₹1,453

Third quarter 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024

Sun Pharmaceutical Industries Limited to Report Q3, 2024 Results on Jan 31, 2024

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm

Sun Pharmaceutical Industries Limited Announces Management Changes

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited to Report Q2, 2024 Results on Nov 01, 2023

Sun Pharmaceutical Industries Limited Announces Presentation of Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 37.76% stake in EzeRx Health Tech Pvt. Ltd. for INR 290 million.

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) signed a binding letter of intent to acquire remaining 25% stake in Sun Pharma de México, S.A. de C.V. from Indi Pharma S.A.P.I. de C.V. for approximately MXN 160 million.

Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2022-2023

Sun Pharmaceutical Industries Limited Declares Final Dividend for the Financial Year 2022-2023

Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries

Price target increased by 7.0% to ₹1,229

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Sun Pharmaceutical Industries Limited Appealed the Patent Litigation Decision Issued by the US District Court for the District of New Jersey Relating to Orexo's Patents Protecting ZUBSOLV®

Upcoming dividend of ₹4.00 per share at 1.0% yield

High number of new directors

Sun Pharmaceutical Industries Limited to Report Q1, 2024 Results on Aug 03, 2023

Sun Pharmaceutical Industries Limited Propose Final Dividend for Fy2022-23, Payable on or Before September 8, 2023

Orexo AB (publ) Wins Patent Litigation for ZUBSOLV in the US Against Sun Pharmaceutical Industries Limited

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Sun Pharma Canada Inc. Announces Health Canada Approval of (PR)ABSORICA LD®? (Isotretinoin Capsules) for Treatment of Severe Nodular Acne

Sun Pharmaceutical Industries Ltd. Presents Data from First-In-Human Phase 1 Studies of Gl0034 At the American Diabetes Association 83Rd Scientific Sessions

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Sun Pharmaceutical Industries Limited Announces Board Appointments

Sun Pharmaceutical Industries Limited to Report Q4, 2023 Results on May 26, 2023

Sun Pharmaceutical Industries Limited Provides Deuruxolitinib Clinical Program Update

Whole Time Director recently sold ₹3.9m worth of stock

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 27.39% stake in Remidio Innovative Solutions Pvt. Ltd. for INR 1.5 billion.

Sun Pharmaceutical Industries Limited Announces US FDA Approval for Generic Lenalidomide Capsules

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sun Pharmaceutical Industries Limited Announces Retirement of Kalyanasundaram Subramanian as Whole-Time Director, Effective February 13, 2023

Sun Pharmaceutical Industries Limited Launches SEZABYTM (Phenobarbital Sodium) in the U.S. for the Treatment of Neonatal Seizures

Sun Pharmaceutical Industries Limited to Report Q3, 2023 Results on Jan 31, 2023

Sun Pharmaceutical Industries Limited Announces One of Its Wholly-Owned Subsidiaries Launch A Novel Anti-Cancer Drug, Palbociclib in India for Patients

Aurinia Pharmaceuticals Inc. Enters into Settlement Agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE

Whole Time Director recently sold ₹9.2m worth of stock

Insider recently sold ₹3.1m worth of stock

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Whole Time Director recently sold ₹10m worth of stock

Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures

Second quarter 2023 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited Approves the Appointment of Sanjay Asher as an Additional Director Designated as an Independent Director

Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

Sun Pharmaceutical Industries Limited to Report Q2, 2023 Results on Nov 01, 2022

Whole Time Director recently sold ₹14m worth of stock